Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA granted accelerated approval to zongertinib, marketed as Hernexeos by Boehringer Ingelheim, for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations.
The indication requires prior systemic therapy and detection by an FDA-approved test. As with other molecularly targeted approvals, the diagnostic step is inseparable from treatment eligibility.
The approval adds another option in a lung-cancer field increasingly divided into molecular subtypes.
Why It Matters
Lung cancer care is becoming more granular, and each molecularly targeted approval increases the importance of comprehensive genomic testing.
What to Watch
Watch confirmatory Beamion LUNG-2 results, sequencing with antibody-drug conjugates and real-world uptake outside major cancer centres.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDALung CancerHER2Targeted Therapy